Eye mounted device for therapeutic agent release
US-12167978-B2 · Dec 17, 2024 · US
US11129984B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11129984-B2 |
| Application number | US-201916516058-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 18, 2019 |
| Priority date | Apr 28, 2006 |
| Publication date | Sep 28, 2021 |
| Grant date | Sep 28, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
In electrically stimulating neural tissue it is important to prevent over stimulation and unbalanced stimulation, which would cause damage to the neural tissue, the electrode, or both. It is critical that neural tissue is not subjected to any direct current or alternating current above a safe threshold. Further, it is important to identify defective electrodes, as continued use may result in neural damage and further electrode damage. The present invention presents system and stimulator control mechanisms to prevent damage to neural tissue.
Opening claim text (preview).
The invention claimed is: 1. A method of stimulating neural tissue comprising: providing an implantable neural stimulator including a plurality of electrodes suitable to stimulate neural tissue; stimulating neural tissue with the neural stimulator, in accordance with external input; testing total power dissipation of the neural stimulator while stimulating tissue, via current through shunt regulators in the neural stimulator; comparing the total power dissipation to a predetermined maximum power dissipation; and reducing stimulation when the total power dissipation exceeds the predetermined maximum power dissipation. 2. The method according to claim 1 , wherein reducing stimulation is discontinuing stimulation. 3. The method according to claim 1 , wherein testing total power dissipation is controlled via an RF power control loop. 4. The method according to claim 1 , wherein testing total power dissipation is testing with a thermistor in the neural stimulator. 5. The method according to claim 1 , wherein the external input is video input from a video processor. 6. The method according to claim 1 , wherein the step of stimulating neural tissue is stimulating visual neural tissue to form artificial vision. 7. The method according to claim 1 , wherein the step of stimulating neural tissue according to external input includes receiving input from multiple sources. 8. The method according to claim 1 , wherein the step of stimulating neural tissue is stimulating with charged balanced cathodic and anodic pulses. 9. The method according to claim 8 , further comprising shorting the plurality of electrodes to ground after the anodic pulses. 10. The method according to claim 9 , further comprising measuring leakage current on each electrode when the electrode is shorted to ground. 11. The method according to claim 10 , further comprising disabling a driver related to an electrode within the plurality of electrodes when leakage current is detected on the electrode. 12. The method according to claim 10 , further comprising transmitting an error signal when leakage current is detected.
of the eye · CPC title
Retinal electrodes · CPC title
for improving safety · CPC title
Selection of the electrode configuration · CPC title
Electrotherapy; Circuits therefor (A61N2/00 takes precedence; irradiation apparatus A61N5/00) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.